bluebird bio, Inc.
bluebird bio, Inc. (BLUE) Stock Competitors & Peer Comparison
See (BLUE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BLUE | $4.97 | +0.00% | 48.7M | -0.24 | -$20.59 | N/A |
| NVO | $45.51 | +2.15% | 202.2B | 10.66 | $4.27 | +3.93% |
| VRTX | $447.97 | +2.46% | 113.7B | 26.55 | $16.87 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $621.52 | -0.99% | 64B | 15.18 | $40.95 | +0.58% |
| ARGX | $838.49 | +2.18% | 51.9B | 37.27 | $22.50 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $305.06 | +3.19% | 40.7B | 76.46 | $3.99 | N/A |
| RVMD | $154.63 | +1.07% | 32.9B | -21.77 | -$7.11 | N/A |
| UTHR | $562.09 | -1.52% | 23.9B | 20.79 | $27.04 | N/A |
Stock Comparison
BLUE vs NVO Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, NVO has a market cap of 202.2B. Regarding current trading prices, BLUE is priced at $4.97, while NVO trades at $45.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas NVO's P/E ratio is 10.66. In terms of profitability, BLUE's ROE is +1.29%, compared to NVO's ROE of +0.66%. Regarding short-term risk, BLUE is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check NVO's competition here
BLUE vs VRTX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, VRTX has a market cap of 113.7B. Regarding current trading prices, BLUE is priced at $4.97, while VRTX trades at $447.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas VRTX's P/E ratio is 26.55. In terms of profitability, BLUE's ROE is +1.29%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, BLUE is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check VRTX's competition here
BLUE vs VRNA Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, BLUE is priced at $4.97, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas VRNA's P/E ratio is -102.80. In terms of profitability, BLUE's ROE is +1.29%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, BLUE and VRNA have similar daily volatility (0.00).Check VRNA's competition here
BLUE vs REGN Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, REGN has a market cap of 64B. Regarding current trading prices, BLUE is priced at $4.97, while REGN trades at $621.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas REGN's P/E ratio is 15.18. In terms of profitability, BLUE's ROE is +1.29%, compared to REGN's ROE of +0.14%. Regarding short-term risk, BLUE is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check REGN's competition here
BLUE vs ARGX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ARGX has a market cap of 51.9B. Regarding current trading prices, BLUE is priced at $4.97, while ARGX trades at $838.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ARGX's P/E ratio is 37.27. In terms of profitability, BLUE's ROE is +1.29%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, BLUE is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ARGX's competition here
BLUE vs SGEN Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BLUE is priced at $4.97, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BLUE's ROE is +1.29%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BLUE is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check SGEN's competition here
BLUE vs ALNY Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ALNY has a market cap of 40.7B. Regarding current trading prices, BLUE is priced at $4.97, while ALNY trades at $305.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ALNY's P/E ratio is 76.46. In terms of profitability, BLUE's ROE is +1.29%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, BLUE is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ALNY's competition here
BLUE vs RVMD Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, RVMD has a market cap of 32.9B. Regarding current trading prices, BLUE is priced at $4.97, while RVMD trades at $154.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas RVMD's P/E ratio is -21.77. In terms of profitability, BLUE's ROE is +1.29%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, BLUE is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check RVMD's competition here
BLUE vs UTHR Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, UTHR has a market cap of 23.9B. Regarding current trading prices, BLUE is priced at $4.97, while UTHR trades at $562.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas UTHR's P/E ratio is 20.79. In terms of profitability, BLUE's ROE is +1.29%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BLUE is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check UTHR's competition here
BLUE vs BNTX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, BNTX has a market cap of 23.6B. Regarding current trading prices, BLUE is priced at $4.97, while BNTX trades at $93.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas BNTX's P/E ratio is -15.84. In terms of profitability, BLUE's ROE is +1.29%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, BLUE is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check BNTX's competition here
BLUE vs INSM Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, INSM has a market cap of 23.5B. Regarding current trading prices, BLUE is priced at $4.97, while INSM trades at $108.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas INSM's P/E ratio is -18.81. In terms of profitability, BLUE's ROE is +1.29%, compared to INSM's ROE of -1.30%. Regarding short-term risk, BLUE is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check INSM's competition here
BLUE vs RPRX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, RPRX has a market cap of 23.4B. Regarding current trading prices, BLUE is priced at $4.97, while RPRX trades at $54.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas RPRX's P/E ratio is 28.67. In terms of profitability, BLUE's ROE is +1.29%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, BLUE is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check RPRX's competition here
BLUE vs ROIV Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ROIV has a market cap of 21.5B. Regarding current trading prices, BLUE is priced at $4.97, while ROIV trades at $29.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ROIV's P/E ratio is -55.35. In terms of profitability, BLUE's ROE is +1.29%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, BLUE is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ROIV's competition here
BLUE vs BGNE Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, BLUE is priced at $4.97, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas BGNE's P/E ratio is -22.55. In terms of profitability, BLUE's ROE is +1.29%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, BLUE is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check BGNE's competition here
BLUE vs INCY Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, INCY has a market cap of 19.5B. Regarding current trading prices, BLUE is priced at $4.97, while INCY trades at $97.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas INCY's P/E ratio is 13.77. In terms of profitability, BLUE's ROE is +1.29%, compared to INCY's ROE of +0.29%. Regarding short-term risk, BLUE is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check INCY's competition here
BLUE vs MRNA Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, MRNA has a market cap of 18.9B. Regarding current trading prices, BLUE is priced at $4.97, while MRNA trades at $47.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas MRNA's P/E ratio is -5.84. In terms of profitability, BLUE's ROE is +1.29%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, BLUE is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check MRNA's competition here
BLUE vs DNA-WT Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BLUE is priced at $4.97, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BLUE's ROE is +1.29%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, BLUE is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check DNA-WT's competition here
BLUE vs GMAB Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, GMAB has a market cap of 16.6B. Regarding current trading prices, BLUE is priced at $4.97, while GMAB trades at $27.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas GMAB's P/E ratio is 20.48. In terms of profitability, BLUE's ROE is +1.29%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, BLUE is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check GMAB's competition here
BLUE vs NBIX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, NBIX has a market cap of 15.7B. Regarding current trading prices, BLUE is priced at $4.97, while NBIX trades at $156.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas NBIX's P/E ratio is 24.06. In terms of profitability, BLUE's ROE is +1.29%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, BLUE is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check NBIX's competition here
BLUE vs JAZZ Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, JAZZ has a market cap of 14.8B. Regarding current trading prices, BLUE is priced at $4.97, while JAZZ trades at $235.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas JAZZ's P/E ratio is 1961.50. In terms of profitability, BLUE's ROE is +1.29%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, BLUE is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check JAZZ's competition here
BLUE vs ASND Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, BLUE is priced at $4.97, while ASND trades at $237.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ASND's P/E ratio is 27.02. In terms of profitability, BLUE's ROE is +1.29%, compared to ASND's ROE of -56.42%. Regarding short-term risk, BLUE is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ASND's competition here
BLUE vs SMMT Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, SMMT has a market cap of 13.5B. Regarding current trading prices, BLUE is priced at $4.97, while SMMT trades at $17.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas SMMT's P/E ratio is -10.95. In terms of profitability, BLUE's ROE is +1.29%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, BLUE is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check SMMT's competition here
BLUE vs BBIO Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, BBIO has a market cap of 13.4B. Regarding current trading prices, BLUE is priced at $4.97, while BBIO trades at $68.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas BBIO's P/E ratio is -18.30. In terms of profitability, BLUE's ROE is +1.29%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, BLUE is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check BBIO's competition here
BLUE vs EXEL Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, EXEL has a market cap of 12.9B. Regarding current trading prices, BLUE is priced at $4.97, while EXEL trades at $51.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas EXEL's P/E ratio is 17.04. In terms of profitability, BLUE's ROE is +1.29%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, BLUE is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check EXEL's competition here
BLUE vs IONS Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, IONS has a market cap of 12.8B. Regarding current trading prices, BLUE is priced at $4.97, while IONS trades at $77.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas IONS's P/E ratio is -38.47. In terms of profitability, BLUE's ROE is +1.29%, compared to IONS's ROE of -0.59%. Regarding short-term risk, BLUE is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check IONS's competition here
BLUE vs KRTX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BLUE is priced at $4.97, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BLUE's ROE is +1.29%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BLUE is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check KRTX's competition here
BLUE vs AXSM Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, AXSM has a market cap of 12B. Regarding current trading prices, BLUE is priced at $4.97, while AXSM trades at $232.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas AXSM's P/E ratio is -62.59. In terms of profitability, BLUE's ROE is +1.29%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, BLUE is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check AXSM's competition here
BLUE vs MDGL Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, BLUE is priced at $4.97, while MDGL trades at $515.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas MDGL's P/E ratio is -38.19. In terms of profitability, BLUE's ROE is +1.29%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, BLUE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check MDGL's competition here
BLUE vs RNAM Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, BLUE is priced at $4.97, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas RNAM's P/E ratio is -17.39. In terms of profitability, BLUE's ROE is +1.29%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, BLUE and RNAM have similar daily volatility (0.00).Check RNAM's competition here
BLUE vs ARWR Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ARWR has a market cap of 11.1B. Regarding current trading prices, BLUE is priced at $4.97, while ARWR trades at $79.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ARWR's P/E ratio is -34.82. In terms of profitability, BLUE's ROE is +1.29%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, BLUE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ARWR's competition here
BLUE vs BMRN Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, BMRN has a market cap of 10.2B. Regarding current trading prices, BLUE is priced at $4.97, while BMRN trades at $52.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas BMRN's P/E ratio is 37.94. In terms of profitability, BLUE's ROE is +1.29%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, BLUE is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check BMRN's competition here
BLUE vs RXDX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BLUE is priced at $4.97, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BLUE's ROE is +1.29%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BLUE is less volatile compared to RXDX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check RXDX's competition here
BLUE vs CYTK Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, BLUE is priced at $4.97, while CYTK trades at $76.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CYTK's P/E ratio is -11.21. In terms of profitability, BLUE's ROE is +1.29%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, BLUE is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check CYTK's competition here
BLUE vs KRYS Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, KRYS has a market cap of 9.1B. Regarding current trading prices, BLUE is priced at $4.97, while KRYS trades at $310.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas KRYS's P/E ratio is 41.43. In terms of profitability, BLUE's ROE is +1.29%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, BLUE is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check KRYS's competition here
BLUE vs IMGN Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BLUE is priced at $4.97, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BLUE's ROE is +1.29%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, BLUE is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check IMGN's competition here
BLUE vs ABVX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, BLUE is priced at $4.97, while ABVX trades at $129.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ABVX's P/E ratio is -24.16. In terms of profitability, BLUE's ROE is +1.29%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, BLUE is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ABVX's competition here
BLUE vs BPMC Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BLUE is priced at $4.97, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BLUE's ROE is +1.29%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, BLUE and BPMC have similar daily volatility (0.00).Check BPMC's competition here
BLUE vs CERE Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BLUE is priced at $4.97, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CERE's P/E ratio is -16.47. In terms of profitability, BLUE's ROE is +1.29%, compared to CERE's ROE of -0.72%. Regarding short-term risk, BLUE is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check CERE's competition here
BLUE vs HALO Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, BLUE is priced at $4.97, while HALO trades at $68.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas HALO's P/E ratio is 23.92. In terms of profitability, BLUE's ROE is +1.29%, compared to HALO's ROE of +1.26%. Regarding short-term risk, BLUE is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check HALO's competition here
BLUE vs IBRX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, IBRX has a market cap of 8.1B. Regarding current trading prices, BLUE is priced at $4.97, while IBRX trades at $7.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas IBRX's P/E ratio is -9.08. In terms of profitability, BLUE's ROE is +1.29%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, BLUE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check IBRX's competition here
BLUE vs NUVL Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, NUVL has a market cap of 8B. Regarding current trading prices, BLUE is priced at $4.97, while NUVL trades at $109.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas NUVL's P/E ratio is -18.03. In terms of profitability, BLUE's ROE is +1.29%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, BLUE is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check NUVL's competition here
BLUE vs TECH Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, TECH has a market cap of 8B. Regarding current trading prices, BLUE is priced at $4.97, while TECH trades at $50.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas TECH's P/E ratio is 72.63. In terms of profitability, BLUE's ROE is +1.29%, compared to TECH's ROE of +0.05%. Regarding short-term risk, BLUE is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check TECH's competition here
BLUE vs PRAX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, PRAX has a market cap of 7.5B. Regarding current trading prices, BLUE is priced at $4.97, while PRAX trades at $352.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas PRAX's P/E ratio is -26.36. In terms of profitability, BLUE's ROE is +1.29%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, BLUE is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check PRAX's competition here
BLUE vs MTSR Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, BLUE is priced at $4.97, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas MTSR's P/E ratio is -23.58. In terms of profitability, BLUE's ROE is +1.29%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, BLUE is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check MTSR's competition here
BLUE vs PCVX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, PCVX has a market cap of 7.4B. Regarding current trading prices, BLUE is priced at $4.97, while PCVX trades at $51.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas PCVX's P/E ratio is -7.41. In terms of profitability, BLUE's ROE is +1.29%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, BLUE is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check PCVX's competition here
BLUE vs CORT Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CORT has a market cap of 7.3B. Regarding current trading prices, BLUE is priced at $4.97, while CORT trades at $68.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CORT's P/E ratio is 195.37. In terms of profitability, BLUE's ROE is +1.29%, compared to CORT's ROE of +0.08%. Regarding short-term risk, BLUE is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check CORT's competition here
BLUE vs IMVT Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, BLUE is priced at $4.97, while IMVT trades at $33.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas IMVT's P/E ratio is -12.09. In terms of profitability, BLUE's ROE is +1.29%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, BLUE is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check IMVT's competition here
BLUE vs MRUS Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, BLUE is priced at $4.97, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas MRUS's P/E ratio is -17.05. In terms of profitability, BLUE's ROE is +1.29%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, BLUE and MRUS have similar daily volatility (0.00).Check MRUS's competition here
BLUE vs ACLX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, BLUE is priced at $4.97, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ACLX's P/E ratio is -28.27. In terms of profitability, BLUE's ROE is +1.29%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, BLUE is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ACLX's competition here
BLUE vs KYMR Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, KYMR has a market cap of 6.7B. Regarding current trading prices, BLUE is priced at $4.97, while KYMR trades at $81.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas KYMR's P/E ratio is -22.20. In terms of profitability, BLUE's ROE is +1.29%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, BLUE is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check KYMR's competition here
BLUE vs ALKS Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ALKS has a market cap of 6.7B. Regarding current trading prices, BLUE is priced at $4.97, while ALKS trades at $39.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ALKS's P/E ratio is 44.38. In terms of profitability, BLUE's ROE is +1.29%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, BLUE is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ALKS's competition here
BLUE vs RETA Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BLUE is priced at $4.97, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas RETA's P/E ratio is -66.29. In terms of profitability, BLUE's ROE is +1.29%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BLUE is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check RETA's competition here
BLUE vs PTGX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, PTGX has a market cap of 6.5B. Regarding current trading prices, BLUE is priced at $4.97, while PTGX trades at $100.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas PTGX's P/E ratio is -55.48. In terms of profitability, BLUE's ROE is +1.29%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, BLUE is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check PTGX's competition here
BLUE vs CELC Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CELC has a market cap of 6.4B. Regarding current trading prices, BLUE is priced at $4.97, while CELC trades at $130.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CELC's P/E ratio is -33.57. In terms of profitability, BLUE's ROE is +1.29%, compared to CELC's ROE of -2.45%. Regarding short-term risk, BLUE is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check CELC's competition here
BLUE vs RYTM Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, BLUE is priced at $4.97, while RYTM trades at $92.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas RYTM's P/E ratio is -29.71. In terms of profitability, BLUE's ROE is +1.29%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, BLUE is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check RYTM's competition here
BLUE vs CNTA Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, BLUE is priced at $4.97, while CNTA trades at $39.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CNTA's P/E ratio is -22.37. In terms of profitability, BLUE's ROE is +1.29%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, BLUE is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check CNTA's competition here
BLUE vs COGT Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, COGT has a market cap of 6B. Regarding current trading prices, BLUE is priced at $4.97, while COGT trades at $35.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas COGT's P/E ratio is -16.30. In terms of profitability, BLUE's ROE is +1.29%, compared to COGT's ROE of -0.83%. Regarding short-term risk, BLUE is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check COGT's competition here
BLUE vs SRRK Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, SRRK has a market cap of 6B. Regarding current trading prices, BLUE is priced at $4.97, while SRRK trades at $49.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas SRRK's P/E ratio is -14.44. In terms of profitability, BLUE's ROE is +1.29%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, BLUE is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check SRRK's competition here
BLUE vs TGTX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, TGTX has a market cap of 5.9B. Regarding current trading prices, BLUE is priced at $4.97, while TGTX trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas TGTX's P/E ratio is 13.57. In terms of profitability, BLUE's ROE is +1.29%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, BLUE is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check TGTX's competition here
BLUE vs BLTE Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, BLUE is priced at $4.97, while BLTE trades at $148.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas BLTE's P/E ratio is -58.27. In terms of profitability, BLUE's ROE is +1.29%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, BLUE is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check BLTE's competition here
BLUE vs PTCT Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, BLUE is priced at $4.97, while PTCT trades at $71.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas PTCT's P/E ratio is -27.97. In terms of profitability, BLUE's ROE is +1.29%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, BLUE is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check PTCT's competition here
BLUE vs CDTX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, BLUE is priced at $4.97, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CDTX's P/E ratio is -19.77. In terms of profitability, BLUE's ROE is +1.29%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, BLUE and CDTX have similar daily volatility (0.00).Check CDTX's competition here
BLUE vs ABCM Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BLUE is priced at $4.97, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BLUE's ROE is +1.29%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BLUE is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ABCM's competition here
BLUE vs LQDA Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, LQDA has a market cap of 5.5B. Regarding current trading prices, BLUE is priced at $4.97, while LQDA trades at $62.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas LQDA's P/E ratio is 364.88. In terms of profitability, BLUE's ROE is +1.29%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, BLUE is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check LQDA's competition here
BLUE vs ISEE Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BLUE is priced at $4.97, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BLUE's ROE is +1.29%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BLUE is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ISEE's competition here
BLUE vs CRSP Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, BLUE is priced at $4.97, while CRSP trades at $56.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CRSP's P/E ratio is -9.14. In terms of profitability, BLUE's ROE is +1.29%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, BLUE is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check CRSP's competition here
BLUE vs CGON Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CGON has a market cap of 5.4B. Regarding current trading prices, BLUE is priced at $4.97, while CGON trades at $60.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CGON's P/E ratio is -25.95. In terms of profitability, BLUE's ROE is +1.29%, compared to CGON's ROE of -0.23%. Regarding short-term risk, BLUE is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check CGON's competition here
BLUE vs APLS Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, BLUE is priced at $4.97, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas APLS's P/E ratio is 38.35. In terms of profitability, BLUE's ROE is +1.29%, compared to APLS's ROE of +0.40%. Regarding short-term risk, BLUE is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check APLS's competition here
BLUE vs LEGN Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, LEGN has a market cap of 5.2B. Regarding current trading prices, BLUE is priced at $4.97, while LEGN trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas LEGN's P/E ratio is -20.48. In terms of profitability, BLUE's ROE is +1.29%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, BLUE is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check LEGN's competition here
BLUE vs FBIOX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, BLUE is priced at $4.97, while FBIOX trades at $25.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas FBIOX's P/E ratio is N/A. In terms of profitability, BLUE's ROE is +1.29%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, BLUE and FBIOX have similar daily volatility (0.00).Check FBIOX's competition here
BLUE vs MIRM Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, MIRM has a market cap of 5B. Regarding current trading prices, BLUE is priced at $4.97, while MIRM trades at $99.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas MIRM's P/E ratio is -7.32. In terms of profitability, BLUE's ROE is +1.29%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, BLUE is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check MIRM's competition here
BLUE vs APGE Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, APGE has a market cap of 4.8B. Regarding current trading prices, BLUE is priced at $4.97, while APGE trades at $77.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas APGE's P/E ratio is -17.97. In terms of profitability, BLUE's ROE is +1.29%, compared to APGE's ROE of -0.33%. Regarding short-term risk, BLUE is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check APGE's competition here
BLUE vs TERN Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, BLUE is priced at $4.97, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas TERN's P/E ratio is -51.41. In terms of profitability, BLUE's ROE is +1.29%, compared to TERN's ROE of -0.20%. Regarding short-term risk, BLUE is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check TERN's competition here
BLUE vs CAI Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, BLUE is priced at $4.97, while CAI trades at $16.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CAI's P/E ratio is -6.04. In terms of profitability, BLUE's ROE is +1.29%, compared to CAI's ROE of +0.06%. Regarding short-term risk, BLUE is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check CAI's competition here
BLUE vs LGND Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, LGND has a market cap of 4.7B. Regarding current trading prices, BLUE is priced at $4.97, while LGND trades at $234.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas LGND's P/E ratio is 30.59. In terms of profitability, BLUE's ROE is +1.29%, compared to LGND's ROE of +0.16%. Regarding short-term risk, BLUE is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check LGND's competition here
BLUE vs FOLD Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, BLUE is priced at $4.97, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas FOLD's P/E ratio is -161.00. In terms of profitability, BLUE's ROE is +1.29%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, BLUE and FOLD have similar daily volatility (0.00).Check FOLD's competition here
BLUE vs AKRO Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, BLUE is priced at $4.97, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas AKRO's P/E ratio is -14.57. In terms of profitability, BLUE's ROE is +1.29%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, BLUE is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check AKRO's competition here
BLUE vs ALPN Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BLUE is priced at $4.97, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BLUE's ROE is +1.29%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, BLUE is less volatile compared to ALPN. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ALPN's competition here
BLUE vs TVTX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, TVTX has a market cap of 4.4B. Regarding current trading prices, BLUE is priced at $4.97, while TVTX trades at $47.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas TVTX's P/E ratio is -95.52. In terms of profitability, BLUE's ROE is +1.29%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, BLUE is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check TVTX's competition here
BLUE vs SYRE Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, BLUE is priced at $4.97, while SYRE trades at $72.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas SYRE's P/E ratio is -34.01. In terms of profitability, BLUE's ROE is +1.29%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, BLUE is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check SYRE's competition here
BLUE vs XENE Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, BLUE is priced at $4.97, while XENE trades at $54.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas XENE's P/E ratio is -11.66. In terms of profitability, BLUE's ROE is +1.29%, compared to XENE's ROE of -0.49%. Regarding short-term risk, BLUE is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check XENE's competition here
BLUE vs MANE Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, BLUE is priced at $4.97, while MANE trades at $102.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas MANE's P/E ratio is -38.86. In terms of profitability, BLUE's ROE is +1.29%, compared to MANE's ROE of -0.95%. Regarding short-term risk, BLUE is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check MANE's competition here
BLUE vs OPT Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BLUE is priced at $4.97, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas OPT's P/E ratio is -1.52. In terms of profitability, BLUE's ROE is +1.29%, compared to OPT's ROE of +0.88%. Regarding short-term risk, BLUE and OPT have similar daily volatility (0.00).Check OPT's competition here
BLUE vs NAMS Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, NAMS has a market cap of 4.1B. Regarding current trading prices, BLUE is priced at $4.97, while NAMS trades at $35.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas NAMS's P/E ratio is -19.90. In terms of profitability, BLUE's ROE is +1.29%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, BLUE is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check NAMS's competition here
BLUE vs MRTX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BLUE is priced at $4.97, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BLUE's ROE is +1.29%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BLUE is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check MRTX's competition here
BLUE vs CPRX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, BLUE is priced at $4.97, while CPRX trades at $31.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CPRX's P/E ratio is 18.09. In terms of profitability, BLUE's ROE is +1.29%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, BLUE is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check CPRX's competition here
BLUE vs VCYT Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, BLUE is priced at $4.97, while VCYT trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas VCYT's P/E ratio is 44.44. In terms of profitability, BLUE's ROE is +1.29%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, BLUE is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check VCYT's competition here
BLUE vs KNSA Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, KNSA has a market cap of 3.8B. Regarding current trading prices, BLUE is priced at $4.97, while KNSA trades at $50.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas KNSA's P/E ratio is 55.87. In terms of profitability, BLUE's ROE is +1.29%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, BLUE is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check KNSA's competition here
BLUE vs CRNX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, BLUE is priced at $4.97, while CRNX trades at $36.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CRNX's P/E ratio is -7.01. In terms of profitability, BLUE's ROE is +1.29%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, BLUE is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check CRNX's competition here
BLUE vs ERAS Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ERAS has a market cap of 3.8B. Regarding current trading prices, BLUE is priced at $4.97, while ERAS trades at $12.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ERAS's P/E ratio is -13.12. In terms of profitability, BLUE's ROE is +1.29%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, BLUE is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ERAS's competition here
BLUE vs DNTH Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, DNTH has a market cap of 3.8B. Regarding current trading prices, BLUE is priced at $4.97, while DNTH trades at $90.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas DNTH's P/E ratio is -21.48. In terms of profitability, BLUE's ROE is +1.29%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, BLUE is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check DNTH's competition here
BLUE vs RYZB Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BLUE is priced at $4.97, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BLUE's ROE is +1.29%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BLUE is less volatile compared to RYZB. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check RYZB's competition here
BLUE vs VKTX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, BLUE is priced at $4.97, while VKTX trades at $32.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas VKTX's P/E ratio is -7.76. In terms of profitability, BLUE's ROE is +1.29%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, BLUE is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check VKTX's competition here
BLUE vs CBAY Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BLUE is priced at $4.97, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BLUE's ROE is +1.29%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BLUE is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check CBAY's competition here
BLUE vs ACAD Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, BLUE is priced at $4.97, while ACAD trades at $21.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas ACAD's P/E ratio is 9.79. In terms of profitability, BLUE's ROE is +1.29%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, BLUE is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check ACAD's competition here
BLUE vs EWTX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, BLUE is priced at $4.97, while EWTX trades at $33.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas EWTX's P/E ratio is -20.06. In terms of profitability, BLUE's ROE is +1.29%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, BLUE is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check EWTX's competition here
BLUE vs SWTX Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, BLUE is priced at $4.97, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas SWTX's P/E ratio is -13.78. In terms of profitability, BLUE's ROE is +1.29%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, BLUE and SWTX have similar daily volatility (0.00).Check SWTX's competition here
BLUE vs BEAM Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, BEAM has a market cap of 3.4B. Regarding current trading prices, BLUE is priced at $4.97, while BEAM trades at $32.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas BEAM's P/E ratio is -66.94. In terms of profitability, BLUE's ROE is +1.29%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, BLUE is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check BEAM's competition here
BLUE vs DNLI Comparison May 2026
BLUE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLUE stands at 48.7M. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, BLUE is priced at $4.97, while DNLI trades at $20.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLUE currently has a P/E ratio of -0.24, whereas DNLI's P/E ratio is -7.27. In terms of profitability, BLUE's ROE is +1.29%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, BLUE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for BLUE.Check DNLI's competition here